Eagle Pharmaceuticals (EGRX) Upgraded by BidaskClub to “Buy”

BidaskClub upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a hold rating to a buy rating in a research note released on Saturday morning.

A number of other brokerages have also weighed in on EGRX. ValuEngine raised shares of Eagle Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, October 2nd. Mizuho reaffirmed a sell rating and set a $37.00 target price on shares of Eagle Pharmaceuticals in a research note on Wednesday, November 8th. Royal Bank Of Canada reissued an outperform rating and set a $75.00 price target (down from $81.00) on shares of Eagle Pharmaceuticals in a research report on Thursday, November 9th. Finally, Piper Jaffray Companies reissued a buy rating and set a $75.00 price target on shares of Eagle Pharmaceuticals in a research report on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of Hold and an average target price of $62.33.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at $58.01 on Friday. The stock has a market cap of $882.17, a price-to-earnings ratio of 9.32 and a beta of 1.24. Eagle Pharmaceuticals has a twelve month low of $45.05 and a twelve month high of $97.15. The company has a debt-to-equity ratio of 0.26, a current ratio of 5.30 and a quick ratio of 5.15.

Eagle Pharmaceuticals declared that its Board of Directors has initiated a stock repurchase program on Wednesday, August 9th that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the specialty pharmaceutical company to purchase up to 13.3% of its shares through open market purchases. Shares repurchase programs are typically a sign that the company’s board believes its shares are undervalued.

Institutional investors have recently modified their holdings of the business. Janus Henderson Group PLC purchased a new position in shares of Eagle Pharmaceuticals during the second quarter valued at approximately $144,384,000. Victory Capital Management Inc. raised its holdings in shares of Eagle Pharmaceuticals by 1.0% during the third quarter. Victory Capital Management Inc. now owns 977,950 shares of the specialty pharmaceutical company’s stock valued at $58,325,000 after purchasing an additional 9,571 shares during the last quarter. Thrivent Financial For Lutherans raised its holdings in shares of Eagle Pharmaceuticals by 17,917.8% during the second quarter. Thrivent Financial For Lutherans now owns 828,820 shares of the specialty pharmaceutical company’s stock valued at $65,386,000 after purchasing an additional 824,220 shares during the last quarter. Iridian Asset Management LLC CT raised its holdings in shares of Eagle Pharmaceuticals by 17.2% during the third quarter. Iridian Asset Management LLC CT now owns 814,214 shares of the specialty pharmaceutical company’s stock valued at $48,560,000 after purchasing an additional 119,327 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Eagle Pharmaceuticals by 23.7% during the second quarter. State Street Corp now owns 696,466 shares of the specialty pharmaceutical company’s stock valued at $54,949,000 after purchasing an additional 133,601 shares during the last quarter.

TRADEMARK VIOLATION WARNING: This article was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.chaffeybreeze.com/2017/12/06/eagle-pharmaceuticals-egrx-upgraded-by-bidaskclub-to-buy.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply